Carbon monoxide abrogates ischemic insult to neuronal cells via the soluble guanylate cyclase-cGMP pathway
PloS one, 2013•journals.plos.org
Purpose Carbon monoxide (CO) is an accepted cytoprotective molecule. The extent and
mechanisms of protection in neuronal systems have not been well studied. We hypothesized
that delivery of CO via a novel releasing molecule (CORM) would impart neuroprotection in
vivo against ischemia-reperfusion injury (IRI)-induced apoptosis of retinal ganglion cells
(RGC) and in vitro of neuronal SH-SY5Y-cells via activation of soluble guanylate-cyclase
(sGC). Methods To mimic ischemic respiratory arrest, SH-SY5Y-cells were incubated with …
mechanisms of protection in neuronal systems have not been well studied. We hypothesized
that delivery of CO via a novel releasing molecule (CORM) would impart neuroprotection in
vivo against ischemia-reperfusion injury (IRI)-induced apoptosis of retinal ganglion cells
(RGC) and in vitro of neuronal SH-SY5Y-cells via activation of soluble guanylate-cyclase
(sGC). Methods To mimic ischemic respiratory arrest, SH-SY5Y-cells were incubated with …
Purpose
Carbon monoxide (CO) is an accepted cytoprotective molecule. The extent and mechanisms of protection in neuronal systems have not been well studied. We hypothesized that delivery of CO via a novel releasing molecule (CORM) would impart neuroprotection in vivo against ischemia-reperfusion injury (IRI)-induced apoptosis of retinal ganglion cells (RGC) and in vitro of neuronal SH-SY5Y-cells via activation of soluble guanylate-cyclase (sGC).
Methods
To mimic ischemic respiratory arrest, SH-SY5Y-cells were incubated with rotenone (100 nmol/L, 4 h) ± CORM ALF186 (10–100 µmol/L) or inactivated ALF186 lacking the potential of releasing CO. Apoptosis and reactive oxygen species (ROS) production were analyzed using flow-cytometry (Annexin V, mitochondrial membrane potential, CM-H2DCFDA) and Western blot (Caspase-3). The impact of ALF186± respiratory arrest on cell signaling was assessed by measuring expression of nitric oxide synthase (NOS) and soluble guanylate-cyclase (sGC) and by analyzing cellular cGMP levels. The effect of ALF186 (10 mg/kg iv) on retinal IRI in Sprague-Dawley rats was assessed by measuring densities of fluorogold-labeled RGC after IRI and by analysis of apoptosis-related genes in retinal tissue.
Results
ALF186 but not inactivated ALF186 inhibited rotenone-induced apoptosis (Annexin V positive cells: 25±2% rotenone vs. 14±1% ALF186+rotenone, p<0.001; relative mitochondrial membrane potential: 17±4% rotenone vs. 55±3% ALF186+rotenone, p<0.05). ALF186 increased cellular cGMP levels (33±5 nmol/L vs. 23±3 nmol/L; p<0.05) and sGC expression. sGC-inhibition attenuated ALF186-mediated protection (relative mitochondrial membrane potential: 55±3% ALF186+rotenone vs. 20±1% ODQ+ALF186+rotenone, p<0.05). ALF186 protected RGC in vivo (IRI 1255±327 RGC/mm2 vs. ALF186+IRI 2036±83; p<0.05) while sGC inhibition abolished the protective effects of ALF186 (ALF186+IRI 2036±83 RGC/mm2 vs. NS-2028+ALF186+IRI 1263±170, p<0.05).
Conclusions
The CORM ALF186 inhibits IRI-induced neuronal cell death via activation of sGC and may be a useful treatment option for acute ischemic insults to the retina and the brain.
PLOS